MR Imaging of Gray Matter Involvement in Multiple Sclerosis: Implications for Understanding Disease Pathophysiology and Monitoring Treatment Efficacy

References

1. 1.↵
   1. Bo L,
   2. Vedeler CA,
   3. Nyland HI,
   4. et al

   . Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 2003;62:723–32

   PubMedWeb of Science
2. 2.↵
   1. Geurts JJ,
   2. Barkhof F

   . Grey matter pathology in multiple sclerosis. Lancet Neurol 2008;7:841–51

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Bo L,
   2. Vedeler CA,
   3. Nyland H,
   4. et al

   . Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 2003;9:323–31

   Abstract/FREE Full Text
4. 4.↵
   1. Filippi M,
   2. Rocca MA

   . Functional MR imaging in multiple sclerosis. Neuroimaging Clin N Am 2009;19:59–70

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Filippi M,
   2. Rocca MA

   . Conventional MRI in multiple sclerosis. J Neuroimaging 2007;17(suppl 1):3S–9S

   CrossRefPubMed
6. 6.↵
   1. Kidd D,
   2. Barkhof F,
   3. McConnell R,
   4. et al

   . Cortical lesions in multiple sclerosis. Brain 1999;122(pt 1):17–26

   Abstract/FREE Full Text
7. 7.↵
   1. Bakshi R,
   2. Ariyaratana S,
   3. Benedict RH,
   4. et al

   . Fluid-attenuated inversion recovery magnetic resonance imaging detects cortical and juxtacortical multiple sclerosis lesions. Arch Neurol 2001;58:742–48

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Geurts JJ,
   2. Pouwels PJ,
   3. Uitdehaag BM,
   4. et al

   . Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology 2005;236:254–60

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Calabrese M,
   2. De Stefano N,
   3. Atzori M,
   4. et al

   . Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol 2007;64:1416–22

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Calabrese M,
    2. Rocca MA,
    3. Atzori M,
    4. et al

    . Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study. Neurology 2009;72:1330–36

    Abstract/FREE Full Text
11. 11.↵
    1. Calabrese M,
    2. Filippi M,
    3. Rovaris M,
    4. et al

    . Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study. Mult Scler 2009;15:36–41

    Abstract/FREE Full Text
12. 12.↵
    1. Calabrese M,
    2. Filippi M,
    3. Rovaris M,
    4. et al

    . Morphology and evolution of cortical lesions in multiple sclerosis: a longitudinal MRI study. Neuroimage 2008;42:1324–28

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Pouwels PJ,
    2. Kuijer JP,
    3. Mugler JP 3rd.,
    4. et al

    . Human gray matter: feasibility of single-slab 3D double inversion-recovery high-spatial-resolution MR imaging. Radiology 2006;241:873–79

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Nelson F,
    2. Poonawalla AH,
    3. Hou P,
    4. et al

    . Improved identification of intracortical lesions in multiple sclerosis with phase-sensitive inversion recovery in combination with fast double inversion recovery MR imaging. AJNR Am J Neuroradiol 2007;28:1645–49

    Abstract/FREE Full Text
15. 15.↵
    1. Nelson F,
    2. Poonawalla A,
    3. Hou P,
    4. et al

    . 3D MPRAGE improves classification of cortical lesions in multiple sclerosis. Mult Scler 2008;14:1214–19

    Abstract/FREE Full Text
16. 16.↵
    1. Kangarlu A,
    2. Bourekas EC,
    3. Ray-Chaudhury A,
    4. et al

    . Cerebral cortical lesions in multiple sclerosis detected by MR imaging at 8 Tesla. AJNR Am J Neuroradiol 2007;28:262–66

    Abstract/FREE Full Text
17. 17.↵
    1. Mainero C,
    2. Benner T,
    3. Radding A,
    4. et al

    . In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI. Neurology 2009;73:941–48. Epub 2009 Jul 29

    Abstract/FREE Full Text
18. 18.↵
    1. Calabrese M,
    2. De Stefano N,
    3. Atzori M,
    4. et al

    . Extensive cortical inflammation is associated with epilepsy in multiple sclerosis. J Neurol 2008;255:581–86

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Roosendaal SD,
    2. Moraal B,
    3. Pouwels PJ,
    4. et al

    . Accumulation of cortical lesions in MS: relation with cognitive impairment. Mult Scler 2009;15:708–14

    Abstract/FREE Full Text
20. 20.↵
    1. Ormerod IE,
    2. Miller DH,
    3. McDonald WI,
    4. et al

    . The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions: a quantitative study. Brain 1987;110(pt 6):1579–616

    Abstract/FREE Full Text
21. 21.↵
    1. Roosendaal SD,
    2. Moraal B,
    3. Vrenken H,
    4. et al

    . In vivo MR imaging of hippocampal lesions in multiple sclerosis. J Magn Reson Imaging 2008;27:726–31

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Filippi M,
    2. Agosta F

    . Magnetization transfer MRI in multiple sclerosis. J Neuroimaging 2007;17(suppl 1):22S–26S

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Hayton T,
    2. Furby J,
    3. Smith KJ,
    4. et al

    . Grey matter magnetization transfer ratio independently correlates with neurological deficit in secondary progressive multiple sclerosis. J Neurol 2009;256:427–35

    CrossRefPubMed
24. 24.↵
    1. Rovaris M,
    2. Judica E,
    3. Sastre-Garriga J,
    4. et al

    . Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. Mult Scler 2008;14:455–64

    Abstract/FREE Full Text
25. 25.↵
    1. Ranjeva JP,
    2. Audoin B,
    3. Au Duong MV,
    4. et al

    . Local tissue damage assessed with statistical mapping analysis of brain magnetization transfer ratio: relationship with functional status of patients in the earliest stage of multiple sclerosis. AJNR Am J Neuroradiol 2005;26:119–27

    Abstract/FREE Full Text
26. 26.↵
    1. Agosta F,
    2. Rovaris M,
    3. Pagani E,
    4. et al

    . Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain 2006;129:2620–27

    Abstract/FREE Full Text
27. 27.↵
    1. Khaleeli Z,
    2. Altmann DR,
    3. Cercignani M,
    4. et al

    . Magnetization transfer ratio in gray matter: a potential surrogate marker for progression in early primary progressive multiple sclerosis. Arch Neurol 2008;65:1454–59

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Rovaris M,
    2. Agosta F,
    3. Pagani E,
    4. et al

    . Diffusion tensor MR imaging. Neuroimaging Clin N Am 2009;19:37–43

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Rovaris M,
    2. Iannucci G,
    3. Falautano M,
    4. et al

    . Cognitive dysfunction in patients with mildly disabling relapsing-remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging. J Neurol Sci 2002;195:103–09

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Rovaris M,
    2. Judica E,
    3. Gallo A,
    4. et al

    . Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. Brain 2006;129:2628–34

    Abstract/FREE Full Text
31. 31.↵
    1. De Stefano N,
    2. Filippi M,
    3. Miller D,
    4. et al

    . Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. Neurology 2007;69:1942–52

    Abstract/FREE Full Text
32. 32.↵
    1. Cifelli A,
    2. Arridge M,
    3. Jezzard P,
    4. et al

    . Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 2002;52:650–53

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Inglese M,
    2. Liu S,
    3. Babb JS,
    4. et al

    . Three-dimensional proton spectroscopy of deep gray matter nuclei in relapsing-remitting MS. Neurology 2004;63:170–72

    Abstract/FREE Full Text
34. 34.↵
    1. Geurts JJ,
    2. Reuling IE,
    3. Vrenken H,
    4. et al

    . MR spectroscopic evidence for thalamic and hippocampal, but not cortical, damage in multiple sclerosis. Magn Reson Med 2006;55:478–83

    CrossRefPubMedWeb of Science
35. 35.↵
    1. Sijens PE,
    2. Mostert JP,
    3. Oudkerk M,
    4. et al

    . (1)H MR spectroscopy of the brain in multiple sclerosis subtypes with analysis of the metabolite concentrations in gray and white matter: initial findings. Eur Radiol 2006;16:489–95. Epub 2005 Jul 19

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Caramanos Z,
    2. DiMaio S,
    3. Narayanan S,
    4. et al

    . (1)H-MRSI evidence for cortical gray matter pathology that is independent of cerebral white matter lesion load in patients with secondary progressive multiple sclerosis. J Neurol Sci 2009;282:72–79. Epub 2009 Feb 20

    CrossRefPubMed
37. 37.↵
    1. Sastre-Garriga J,
    2. Ingle GT,
    3. Chard DT,
    4. et al

    . Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis. Arch Neurol 2005;62:569–73

    CrossRefPubMedWeb of Science
38. 38.↵
    1. Neema M,
    2. Stankiewicz J,
    3. Arora A,
    4. et al

    . T1- and T2-based MRI measures of diffuse gray matter and white matter damage in patients with multiple sclerosis. J Neuroimaging 2007;17(suppl 1):16S–21S

    CrossRefPubMedWeb of Science
39. 39.↵
    1. Niepel G,
    2. Tench ChR,
    3. Morgan PS,
    4. et al

    . Deep gray matter and fatigue in MS: a T1 relaxation time study. J Neurol 2006;253:896–902. Epub 2006 Mar 13

    CrossRefPubMedWeb of Science
40. 40.↵
    1. Dalton CM,
    2. Chard DT,
    3. Davies GR,
    4. et al

    . Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004;127:1101–07

    Abstract/FREE Full Text
41. 41.↵
    1. Tiberio M,
    2. Chard DT,
    3. Altmann DR,
    4. et al

    . Gray and white matter volume changes in early RRMS: a 2-year longitudinal study. Neurology 2005;64:1001–07

    Abstract/FREE Full Text
42. 42.↵
    1. Valsasina P,
    2. Benedetti B,
    3. Rovaris M,
    4. et al

    . Evidence for progressive gray matter loss in patients with relapsing-remitting MS. Neurology 2005;65:1126–28

    Abstract/FREE Full Text
43. 43.↵
    1. Sastre-Garriga J,
    2. Ingle GT,
    3. Chard DT,
    4. et al

    . Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. Brain 2005;128:1454–60

    Abstract/FREE Full Text
44. 44.↵
    1. Tedeschi G,
    2. Lavorgna L,
    3. Russo P,
    4. et al

    . Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology 2005;65:280–85

    Abstract/FREE Full Text
45. 45.↵
    1. Chen JT,
    2. Narayanan S,
    3. Collins DL,
    4. et al

    . Relating neocortical pathology to disability progression in multiple sclerosis using MRI. Neuroimage 2004;23:1168–75

    CrossRefPubMedWeb of Science
46. 46.↵
    1. Fisher E,
    2. Lee JC,
    3. Nakamura K,
    4. et al

    . Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008;64:255–65

    CrossRefPubMedWeb of Science
47. 47.↵
    1. Amato MP,
    2. Bartolozzi ML,
    3. Zipoli V,
    4. et al

    . Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology 2004;63:89–93

    Abstract/FREE Full Text
48. 48.↵
    1. Benedict RH,
    2. Bruce JM,
    3. Dwyer MG,
    4. et al

    . Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol 2006;63:1301–06

    CrossRefPubMedWeb of Science
49. 49.↵
    1. Henry RG,
    2. Shieh M,
    3. Okuda DT,
    4. et al

    . Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry 2008;79:1236–44

    Abstract/FREE Full Text
50. 50.↵
    1. Prinster A,
    2. Quarantelli M,
    3. Orefice G,
    4. et al

    . Grey matter loss in relapsing-remitting multiple sclerosis: a voxel-based morphometry study. Neuroimage 2006;29:859–67

    CrossRefPubMedWeb of Science
51. 51.↵
    1. Bendfeldt K,
    2. Kuster P,
    3. Traud S,
    4. et al

    . Association of regional gray matter volume loss and progression of white matter lesions in multiple sclerosis: a longitudinal voxel-based morphometry study. Neuroimage 2009;45:60–67

    CrossRefPubMedWeb of Science
52. 52.↵
    1. Ceccarelli A,
    2. Rocca MA,
    3. Pagani E,
    4. et al

    . A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes. Neuroimage 2008;42:315–22

    CrossRefPubMedWeb of Science
53. 53.↵
    1. Sepulcre J,
    2. Sastre-Garriga J,
    3. Cercignani M,
    4. et al

    . Regional gray matter atrophy in early primary progressive multiple sclerosis: a voxel-based morphometry study. Arch Neurol 2006;63:1175–80

    CrossRefPubMedWeb of Science
54. 54.↵
    1. Mesaros S,
    2. Rocca MA,
    3. Absinta M,
    4. et al

    . Evidence of thalamic gray matter loss in pediatric multiple sclerosis. Neurology 2008;70:1107–12

    Abstract/FREE Full Text
55. 55.↵
    1. Morgen K,
    2. Sammer G,
    3. Courtney SM,
    4. et al

    . Evidence for a direct association between cortical atrophy and cognitive impairment in relapsing-remitting MS. Neuroimage 2006;30:891–98

    CrossRefPubMedWeb of Science
56. 56.↵
    1. Benedict RH,
    2. Zivadinov R,
    3. Carone DA,
    4. et al

    . Regional lobar atrophy predicts memory impairment in multiple sclerosis. AJNR Am J Neuroradiol 2005;26:1824–31

    Abstract/FREE Full Text
57. 57.↵
    1. Sicotte NL,
    2. Kern KC,
    3. Giesser BS,
    4. et al

    . Regional hippocampal atrophy in multiple sclerosis. Brain 2008;131:1134–41

    Abstract/FREE Full Text
58. 58.↵
    1. Sepulcre J,
    2. Masdeu JC,
    3. Goni J,
    4. et al

    . Fatigue in multiple sclerosis is associated with the disruption of frontal and parietal pathways. Mult Scler 2009;15:337–44

    Abstract/FREE Full Text
59. 59.↵
    1. Anderson V,
    2. Fisniku L,
    3. Altmann D,
    4. et al

    . MRI measures show significant cerebellar gray matter volume loss in multiple sclerosis and are associated with cerebellar dysfunction. Mult Scler 2009;15:811–17

    Abstract/FREE Full Text
60. 60.↵
    1. Sailer M,
    2. Fischl B,
    3. Salat D,
    4. et al

    . Focal thinning of the cerebral cortex in multiple sclerosis. Brain 2003;126:1734–44

    Abstract/FREE Full Text
61. 61.↵
    1. Mesaros S,
    2. Rovaris M,
    3. Pagani E,
    4. et al

    . A magnetic resonance imaging voxel-based morphometry study of regional gray matter atrophy in patients with benign multiple sclerosis. Arch Neurol 2008;65:1223–30

    CrossRefPubMedWeb of Science
62. 62.↵
    1. Audoin B,
    2. Ranjeva JP,
    3. Au Duong MV,
    4. et al

    . Voxel-based analysis of MTR images: a method to locate gray matter abnormalities in patients at the earliest stage of multiple sclerosis. J Magn Reson Imaging 2004;20:765–71

    CrossRefPubMedWeb of Science
63. 63.↵
    1. Davies GR,
    2. Altmann DR,
    3. Rashid W,
    4. et al

    . Emergence of thalamic magnetization transfer ratio abnormality in early relapsing-remitting multiple sclerosis. Mult Scler 2005;11:276–81

    Abstract/FREE Full Text
64. 64.↵
    1. Audoin B,
    2. Fernando KT,
    3. Swanton JK,
    4. et al

    . Selective magnetization transfer ratio decrease in the visual cortex following optic neuritis. Brain 2006;129:1031–39

    Abstract/FREE Full Text
65. 65.↵
    1. Khaleeli Z,
    2. Cercignani M,
    3. Audoin B,
    4. et al

    . Localized grey matter damage in early primary progressive multiple sclerosis contributes to disability. Neuroimage 2007;37:253–61

    CrossRefPubMedWeb of Science
66. 66.↵
    1. Ceccarelli A,
    2. Rocca MA,
    3. Valsasina P,
    4. et al

    . A multiparametric evaluation of regional brain damage in patients with primary progressive multiple sclerosis. Hum Brain Mapp 2009;30:3009–19

    CrossRefPubMedWeb of Science
67. 67.↵
    1. Bodini B,
    2. Khaleeli Z,
    3. Cercignani M,
    4. et al

    . Exploring the relationship between white matter and gray matter damage in early primary progressive multiple sclerosis: an in vivo study with TBSS and VBM. Hum Brain Mapp 2009;30:2852–61

    CrossRefPubMedWeb of Science
68. 68.↵
    1. Ciccarelli O,
    2. Wheeler-Kingshott CA,
    3. McLean MA,
    4. et al

    . Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosis. Brain 2007;130:2220–31

    Abstract/FREE Full Text
69. 69.↵
    1. Agosta F,
    2. Pagani E,
    3. Caputo D,
    4. et al

    . Associations between cervical cord gray matter damage and disability in patients with multiple sclerosis. Arch Neurol 2007;64:1302–05

    CrossRefPubMedWeb of Science
70. 70.↵
    1. Rocca MA,
    2. Colombo B,
    3. Falini A,
    4. et al

    . Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. Lancet Neurol 2005;4:618–26

    CrossRefPubMedWeb of Science
71. 71.↵
    1. Mezzapesa DM,
    2. Rocca MA,
    3. Rodegher M,
    4. et al

    . Functional cortical changes of the sensorimotor network are associated with clinical recovery in multiple sclerosis. Hum Brain Mapp 2008;29:562–73

    CrossRefPubMedWeb of Science
72. 72.↵
    1. Filippi M,
    2. Rocca MA,
    3. Falini A,
    4. et al

    . Correlations between structural CNS damage and functional MRI changes in primary progressive MS. Neuroimage 2002;15:537–46

    CrossRefPubMed
73. 73.↵
    1. Penner IK,
    2. Rausch M,
    3. Kappos L,
    4. et al

    . Analysis of impairment related functional architecture in MS patients during performance of different attention tasks. J Neurol 2003;250:461–72

    CrossRefPubMedWeb of Science
74. 74.↵
    1. Rocca MA,
    2. Agosta F,
    3. Colombo B,
    4. et al

    . fMRI changes in relapsing-remitting multiple sclerosis patients complaining of fatigue after IFNbeta-1a injection. Hum Brain Mapp 2007;28:373–82

    CrossRefPubMedWeb of Science
75. 75.↵
    1. Fazekas F,
    2. Soelberg-Sorensen P,
    3. Comi G,
    4. et al

    . MRI to monitor treatment efficacy in multiple sclerosis. J Neuroimaging 2007;17(suppl 1):50S–55S

    CrossRefPubMedWeb of Science
76. 76.↵
    1. Kaiser CC,
    2. Shukla DK,
    3. Stebbins GT,
    4. et al

    . A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. J Neuroimmunol 2009;211:124–30. Epub 2009 May 15

    CrossRefPubMed
77. 77.↵
    1. Rocca MA,
    2. Agosta F,
    3. Sormani MP,
    4. et al

    . A three-year, multi-parametric MRI study in patients at presentation with CIS. J Neurol 2008;255:683–91

    CrossRefPubMedWeb of Science
78. 78.↵
    1. Narayana PA,
    2. Wolinsky JS,
    3. Rao SB,
    4. et al

    . Multicentre proton magnetic resonance spectroscopy imaging of primary progressive multiple sclerosis. Mult Scler 2004;10(suppl 1):S73–78

    Abstract/FREE Full Text
79. 79.↵
    1. Sajja BR,
    2. Narayana PA,
    3. Wolinsky JS,
    4. et al

    . Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study. Mult Scler 2008;14:73–80. Epub 2007 Sep 19

    Abstract/FREE Full Text
80. 80.↵
    1. Wegner C,
    2. Filippi M,
    3. Korteweg T,
    4. et al

    . Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol 2008;15:113–22

    PubMedWeb of Science
81. 81.↵
    1. Rocca MA,
    2. Absinta M,
    3. Valsasina P,
    4. et al

    . Abnormal connectivity of the sensorimotor network in patients with MS: a multicenter fMRI study. Hum Brain Mapp 2009;30:2412–25

    CrossRefPubMedWeb of Science